**CURRICULUM VITAE
Peter J. Tebben, MD**

**Version date:** July 9, 2024

**Proposed for:** Associate Professor, CES Track

**Term:** 10/2024-06/2029

**School:** Yale School of Medicine

**Education:**
1990-1991 BGS, Kansas State University, Manhattan, Kansas
1992-1994 BGS, University of Kansas, Lawrence, Kansas
1994-1998 MD, University of Kansas, Lawrence, Kansas

**Career/Academic Appointments:**

1998-2002 Resident, Internal Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota

2002-2004 Fellow, Adult Endocrinology, Mayo Clinic, Rochester, Minnesota

2004-2006 Fellow, Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota

1/2005-7/2007 Instructor of Medicine, Mayo Clinic College of Science and Medicine, Rochester, Minnesota

7/2006-6/2009 Senior Associate Consultant, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

7/2006-6/2009 Senior Associate Consultant (joint appointment), Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota

8/2007-5/2021 Assistant Professor of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

8/2007-5/2021 Assistant Professor of Pediatrics, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

6/2009-2/2011 Consultant, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

6/2009-2/2011 Consultant (joint appointment), Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota

2/2011-8/2012 Consultant, Adult and Pediatric Endocrinology, Oklahoma City, Oklahoma

8/2012-Present Consultant, Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota

8/2012-Present Consultant (joint appointment), Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

6/2021-Present Associate Professor of Pediatrics, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

6/2021-Present Associate Professor of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

**Administrative Positions:**

2006-Present Member, Bone Core Group, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

2009-2010 Member, Endocrine Research Committee, Mayo Clinic, Rochester, Minnesota

2012-Present Director of the Mayo Clinic Pediatric Metabolic Bone Clinic

2012-Present Clinical Competency Committee, Pediatric Endocrine Fellowship Program, Mayo Clinic, Rochester, Minnesota

2012-Present Member, Pediatric Endocrine Fellowship Scholarship Oversight Committee, Mayo Clinic, Rochester, Minnesota

2014-2023 Member, Mayo Clinic Institutional Review Board, Mayo Clinic, Rochester, Minnesota

2016-Present Content Reviewer, Ask Mayo Expert Committee, Mayo Clinic, Rochester, Minnesota

2018 Pediatric Endocrine Faculty Search Committee, Mayo Clinic, Rochester, Minnesota

2019 Pediatric Nephrology Faculty Search Committee, Mayo Clinic, Rochester, Minnesota

2020-2023 Member, Adult Endocrine Fellows Career Development Mentoring Committee (CDMC), Mayo Clinic, Rochester, Minnesota

2023-Present Chair, Pediatric and Adolescent Research Committee, Mayo Clinic, Rochester, Minnesota

2023-Present Member, Rochester and Midwest Outpatient Practice Sub-Committee, Rochester, Minnesota

**Board Certification:**

2002-2012 American Board of Internal Medicine (ABIM), Internal Medicine

2014-Present American Board of Internal Medicine (ABIM), Endocrinology, Diabetes and Metabolism

2004-2014 American Board of Pediatrics, Pediatrics

2017-Present American Board of Pediatrics, Pediatrics/Pediatric Endocrinology

**Professional Honors & Recognition:**

***International/ National/Regional:***

2020 Top Doctor 2020, Minnesota Monthly Magazine, Bloomington, Minnesota

***University (Mayo Clinic), Rochester, Minnesota:***

01/2005 Randall G. Sprague Award in Endocrinology and Metabolism

07/2008 Department of Medicine Career Development Time Award

2014 Faculty Education Recognition Award

2019-2023 Top Performer (99th%) Mayo Clinic Patient Experience

**Grant/Clinical Trials History:**

***Current Grants:***

Agency: Mayo Clinic Development Funds

ID#: N/A

Title: 24-hydrozylase Deficiency and CYP24A1 Mutation Patient Registry

Co-PI: P. Tebben

Percent Effort:

Total Costs: $85,000

Project Period: 10/2017 - Present

Agency: Inozyme Pharma, Inc.

ID#: INZ701-101

Title: Amend #2 | A Phase ½, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701, Followed by an Open-Label, Long-Term Extension Period in Adults with ENPP1 Deficiency

Co-PI: P. Tebben

Percent Effort:

Total Costs:

Project Period: 12/2021 - Present

Agency: Calcilytix Therapeutics, Inc

ID#: CLTX-305-901

Title: Autosomal Dominant Hypocalcemia Types 1 and 2 (ADH1/2) Disease Monitoring Study

PI: P. Tebben

Percent Effort:

Total Costs:

Project Period: 06/2022 – Present

Agency: Calcilytix Therapeutics, Inc

ID#: CLTX-305-302

Title: CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants with ADH1

PI: P. Tebben

Percent Effort:

Total Costs:

Project Period: 06/2023 – Present

Agency: Amgen

ID#: 20200105-EVENITY

Title: A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

PI: P. Tebben

Percent Effort:

Total Costs:

Project Period: 06/2023 – Present

***Past Grants:***

Agency: NPS Pharmaceuticals, Inc.

ID#: CL1-11-040

Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP 558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)] for the Treatment of Adults with Hypoparathyroidism

Co-I: P. Tebben

Percent Effort:

Total Costs:

Project Period: 02/2009 - 02/2010

Agency: NPS Pharmaceuticals, Inc.

ID#: C09-002

Title: An Open-Label, Escalating, Single-Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of NPSP558 Administered Subcutaneously to Subjects with Hypoparathyroidism

Co-I: P.Tebben

Percent Effort:

Total Costs:

Project Period: 03/2010 - 09/2010

Agency: Alexion Pharmaceuticals, Inc.

ID#: ALX-HPP-501

Title: An Observational, Longitudinal, Prospective, Long-Term Registry of Patients with Hypophosphatasia

PI: P. Tebben

Percent Effort:

Total Costs:

Project Period: 10/2015 - 03/2019

**Invited Speaking Engagements, Presentations & Workshops**

***International/National:***

1. “Granulomatous Hypophysitis after Interferon Alpha and Ribavirin Therapy.” The Endocrine Society Annual Meeting, Philadelphia, Pennsylvania, 2003
2. “Development of Graves’ Disease under Adequate Immunosuppression in a Cardiac Transplant Patient.” (Poster presentation). American Thyroid Association Conference, Falls Church, Virginia, 2003
3. “Elevation of Alkaline Phosphatase Levels after Roux-en-y Gastric Bypass.” (Poster presentation). North American Association for the Study of Obesity Conference, Fort Lauderdale, Florida, 2003
4. “Elevated Serum Fibroblast Growth Factor 23 in Patients with Small Cell and Squamous Cell Lung Cancer with Normal Serum Phosphorus”, “Elevated Serum Fibroblast Growth Factor 23 without Changes in Phosphorus in Women with Advanced Stage Malignant Ovarian Tumors,” and “Fibroblast Growth Factor 23, Parathyroid Hormone, and 1 Alpha, 25 dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism.” (Poster presentations). American Society for Bone and Mineral Research, Seattle, Washington, 2004
5. “Whole Body 99m-Tc Sestamibi Scintigraphy to Localize Tumors Causing Oncogenic Osteomalacia.” (Poster presentation). American Association of Clinical Endocrinologists Conference, Washington, DC, 2005
6. “Parathyroid Carcinoma.” American Society for Bone and Mineral Research, Adult Bone and Mineral Working Group, Philadelphia, Pennsylvania, 2006
7. “A New Pediatric Sclerosing Bone Disorder Featuring Fragility Fractures.” (Poster presentation). American Society for Bone and Mineral Research Annual Meeting, Philadelphia, Pennsylvania, 2006
8. “Hypophosphatasia in a Child with Overgrowth Syndrome.” (Poster presentation). Endocrine Society Annual Meeting, Boston, Massachusetts, 2006
9. “Rickets around the World.” International Conference on Rickets, Dhaka, Bangladesh, 2006
10. “Use of Teriparatide in Hajdu-Cheney Syndrome.” American Society for Bone and Mineral Research, Adult Bone and Mineral Working Group, Honolulu, Hawaii, 2007
11. “Nutritional Rickets.” Advances and Controversies in Clinical Nutrition, 17th Annual Meeting, Savannah, Georgia, 2007
12. “Growth Hormone Therapy: Bridging the Gap.” Endocrine Society Annual Meeting, Toronto, Canada, 2007
13. “Use of Teriparatide in Hajdu-Cheney Syndrome.” (Poster presentation). American Society for Bone and Mineral Research Annual Meeting, Honolulu, Hawaii, 2007
14. “Bone Health in Children and Adolescents” and “Growth Hormone Treatment after Attainment of Final Adult Height.” Mayo Clinic Endocrine Course, Palma, Spain, 2008
15. “Vitamin D Supplementation in Infants and Children.” Advances and Controversies in Clinical Nutrition, Amelia Island, Florida, 2009
16. “A Novel Syndrome of Hypercalcemia Due to Mutations in the CYP24A1 Gene.” American Society for Bone and Mineral Research Annual Meeting, San Diego, California, 2011
17. “Genetics of Congenital Hypothyroidism.” 17th Annual French/American Endocrine Meeting, Paris, France, 2014
18. “Osteoporosis: Current Concepts in Management.” Indian Head Symposium, Cable, Wisconsin, 2014
19. “Diagnosing Hypophosphatasia: Genetic, Biochemical, and Radiologic Testing, Endocrine Society CME Ancillary Symposium, San Diego, California, 2015
20. “Iron Replacement as a Therapeutic Approach for Renal Phosphate Wasting with Associated Iron Deficiency.” (Poster presentation). Endocrine Society Annual Meeting, San Diego, California, 2015
21. “Pediatric Endocrinology: Meet the Professor.” Endocrine University. Indianapolis/Lafayette/Bloomington, Indiana, 2015
22. “The Clinical Spectrum of Hypophosphatasia.” Endocrine Society Annual Meeting, Boston, Massachusetts, 2016
23. “Prevalence of Metabolic Bone Disease in Children Receiving Elemental Formula.” American Society for Bone and Mineral Research Annual Meeting, Denver, Colorado, 2017
24. “Practical Approaches to Diagnosing and Treating Hereditary Hypophasphatemic Disorders: An Interactive Discussion” and “Hypophasphatemic Rickets, Evaluation and Management.” Endocrine Society Annual Meeting, Chicago, Illinois, 2018
25. “Hypophosphatemica in Adults, the Broad Range of Severity.” First Annual Hypophosphatemia Scientific Meeting (Soft Bones), Chicago, IL, 2018
26. “Hypophosphatemic Rickets: Diagnostic and Management Strategies.” Children’s Mercy Hospital Annual Conference, Kansas City, Missouri, 2018
27. “Treatment of non-FGF23 Mediated Hypophosphatemic Disorders.” Endocrine Society Annual Meeting, New Orleans, Louisiana, 2019
28. “Evaluation and Management of Hypophosphatemia in Children: Focus on X-Linked Hypophosphatemic Rickets.” Vietnam National Children’s Hospital Annual Pediatric Conference, Hanoi, Vietnam, 2019
29. “Hypoparathyroidism in Children: Diagnosis and Management.” HypoPARAthyroidism Association Annual Meeting (Virtual, due to Covid), 2020
30. “Evaluation of the Patient with Hypophosphatemia: Diagnosis and Treatment.” Endocrine Society Annual Meeting (Virtual, due to Covid), 2021
31. “Clinical Approach to Hypophosphatemia.” American Academy of Clinical Endocrinology Annual Meeting (Virtual, due to Covid), 2021
32. “Evaluation of the Patient with Hypophosphatemia: Diagnosis and Management.” Iran Endocrine Society: 13th International Congress of Endocrine Disorders (Virtual, due to Covid), 2021
33. “Adult Hypophosphatasia: An Uncommon Bone Disease Hiding in Plain Sight.” American Bone Health “Bonesense” Speaker Series (Virtual, due to Covid), 2022
34. “Approach to the Patient with Hypophosphatemia.” Clinical Endocrinology Update Meeting (Virtual, due to Covid), 2022
35. “Pediatric to Adult Transitions for Bone Disorders.” Clinical Endocrinology Update Meeting (Virtual, due to Covid), 2022
36. “Hypophosphatasia and Hypercalcemia.” Soft Bones Tele ECHO program (Virtual, due to Covid), 2022
37. “Hypoparathyroidism: Diagnosis and Management.” Mayo Clinic Endocrine Update, Lahaina, Hawaii, 2022
38. “Selected Bone Disorders During Adolescence: A case-based discussion.” The Medical City in Manila Philippines Bone Summit, (Virtual, due to Covid), 2022
39. “Hypophosphatasia or Osteoporosis: A clinical conundrum.” Soft Bones Scientific Meeting, Bethesda, MD, 2023
40. “Hypophosphatasia in Adults.” Soft Bones Scientific Meeting, Phoenix AZ, 2023
41. “Approach to the patient with hypophosphatemia.” Mayo Thyroid and Parathyroid Disorders Course, Orlando, FL, 2023
42. “Genetic Causes of Hypre- and Hypocalcemia.” Mayo Thyroid and Parathyroid Disorders Course, Orlando, FL, 2023
43. “24-Hydroxylase Mutations: Phenotypic Spectrum and Treatment.” Yale School of Medicine, Section of Endocrinology Grand Rounds, New Haven, CT, 2023
44. “Primer for Rare Bone Disease.” Mayo Endocrine Update, Grand Rio Mar, Puerto Rico, 2024

***Regional:***

1. “Nutritional Rickets.” Pediatric Grand Rounds, Mayo Clinic, Rochester, Minnesota, 2007
2. “Idiopathic Juvenile Osteoporosis.” Mayo Clinic, Endocrinology Grand Rounds, Rochester, Minnesota, 2008
3. “Bone Health in Children.” Mayo Clinic, Clinical Reviews, Rochester, Minnesota, 2008
4. “Thyroid and Parathyroid Disease.” Mayo Clinic Internal Medicine Board Review, Rochester, Minnesota, 2009 & 2010
5. “Osteoporosis in Children.” Mayo Clinic PMR Conference, Rochester, Minnesota, 2010
6. “Vitamin D: Bone and Beyond.” Mayo Pediatric Days, Chicago, Illinois, 2010 & 2011
7. “Hypoparathyroidism.” American Association of Clinical Endocrinologists, Minnesota Midwest Regional Annual Meeting, Minneapolis, MN, 2013
8. “Bone and Calcium Disorders.” Mayo Clinic Internal Board Review, Rochester, Minnesota, 2013
9. “Diabetes and Hypoglycemia.” Mayo Clinic Internal Board Review, Rochester, Minnesota, 2013
10. “Pediatric Endocrinology: Meet the Professor.” Mayo Clinic Endocrine Course, Scottsdale, Arizona, 2014
11. “Calcium and Vitamin D Pathophysiology.” Mayo Medical School, Rochester, Minnesota, 2014
12. “Syndrome of Hypercalcemia Due to Mutations in the CYP24A1 Gene.” Endocrine Grand Rounds, Mayo Clinic, Rochester, Minnesota, 2014
13. “Syndrome of Hypercalcemia Due to Mutations in the CYP24A1 Gene.” Nephrology Grand Rounds, Mayo Clinic, Rochester, Minnesota, 2014
14. “Diabetes and Hypoglycemia.” Mayo Internal Medicine Board Review, Rochester, Minnesota, 2014
15. “Thyroid Pearls.” Mayo Clinic Clinical Reviews, Rochester, Minnesota, 2014
16. “Fractures in Adolescents and Young Adults.” Mayo Endocrine Update, Rochester, Minnesota, 2017
17. “Improved Frequency of Waist Circumference Measurement and utilization of Weight-to-Height Ratio in Cardiometabolic Risk Counseling among Children: A Quality Improvement Project.” (Poster presentation.) Mayo Clinic Quality Conference, Rochester, Minnesota, 2017
18. “Fractures and Bisphosphonate Use in Children and Young Adults.” Mayo Clinic Children’s Joint Grand Rounds, Phoenix, Arizona, 2018
19. “X-Linked Hypophosphatemic Rickets: Diagnosis and Management.” American Association of Clinical Endocrinologists Midwest Chapter Meeting, Bloomington, Minnesota, 2019
20. “Primary Hyperparathyroidism: Evaluation and Management.” Mayo Clinic School of Continuous Professional Development 95th Annual Clinical Reviews Conference, Rochester, Minnesota, 2021
21. “FGF23 Mediated Hypophosphatemia Diagnosis and Management.” Washington University Skeletal Health Multi-Disciplinary Case Conference Series (Virtual due to Covid), 2022
22. “Primary Hyperparathyroidism: Evaluation and Management.” Mayo Clinic School of Continuous Professional Development 42nd Annual Practice of Internal Medicine Conference, Rochester, Minnesota, 2022

**Professional Service:**

***Professional Organizations:***

American Society for Bone and Mineral Reseach

2002-Present Member

2014-2015 Chairperson, Pediatric Bone and Mineral Working Group

2016-2023 Committee Member, Pediatric Bone and Mineral Working Group Committee

2019 Member, Program Committee for Annual Meeting

International Society for Clinical Densitometry

2018 Clinical Practice Guidelines Task Force for Pediatric Bone Density

**Bibliography:**

***Peer-Reviewed Original Research***

1. **Tebben PJ,** Pope TW, Hinson G, Batnitzky S, Wetzel LH, DePaolis DC, Munns S, Wilkinson SB, Gordon MA. Three-dimensional computerized reconstruction. Illustration of incremental articular cartilage thinning. Invest Radiol. 1997 Aug; 32(8):475-84. PMID: 9258736
2. **Tebben PJ,** Singh RJ, Clarke BL, Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25- dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc. 2004 Dec; 79

(12):1508-13 PMID: 15595334 DOI: 10.4065/79.12.1508

1. **Tebben PJ**, Kalli KR, Cliby WA, Hartmann LC, Grande JP, Singh RJ, Kumar R. Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc. 2005 Jun; 80 (6):745-51 PMID: 15948297 DOI: 10.1016/S0025-6196(11)61528-0
2. Hodgson SF, Clarke BL, **Tebben PJ**, Mullan BP, Cooney WP 3rd, Shives TC. Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy. Endocr Pract. 2006 Jan-Feb; 12 (1):35-42 PMID: 16524861 DOI: 10.4158/EP.12.1.35
3. Berndt TJ, Bielesz B, Craig TA, **Tebben PJ**, Bacic D, Wagner CA, O'Brien S, Schiavi S, Biber J, Murer H, Kumar R. Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells. Pflugers Arch. 2006 Jan; 451 (4):579-87 Epub 2005 Sept 09 PMID: 16151791 DOI: 10.1007/s00424-005-1495-2
4. **Tebben PJ**, Atkinson JL, Scheithauer BW, Erickson D. Granulomatous adenohypophysitis after interferon and ribavirin therapy. Endocr Pract. 2007 Mar-Apr; 13 (2):169-75 PMID: 17490932 DOI: 10.4158/EP.13.2.169
5. Ellison J, **Tebben P**. Novel human pathological mutations. Gene symbol: PHEX. Disease: rickets, hypophosphataemic. Hum Genet. 2009 Apr; 125(3):339. PMID: 19309785
6. Kirmani S, **Tebben PJ**, Lteif AN, Gordon D, Clarke BL, Hefferan TE, Yaszemski MJ, McGrann PS, Lindor NM, Ellison JW. Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys- Dietz syndrome. Am J Med Genet A. 2010 Apr; 152A (4):1016-9 PMID: 20358619 DOI: 10.1002/ajmg.a.33356
7. Dy BM, Vazquez B, **Tebben PJ**, Kumar S, Thompson GB. Severe hypercalcemia due to primary hyperparathyroidism with MEN 2A. World J Endocr Surg.2010;2:(3):131-3.
8. **Tebben PJ**, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y, Foreman JW, Chelminski PR, Kumar

R. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab. 2012 Mar; 97(3):E423-7. Epub 2012 Feb 15. PMID: 22337913 PMCID: 3319216 DOI: 10.1210/jc.2011-1935

1. Kumar R, **Tebben PJ**, Thompson JR. Vitamin D and the kidney. Arch Biochem Biophys. 2012 Jul 1; 523

(1):77-86 Epub 2012 Mar 15 PMID: 22426203 PMCID: 3361542 DOI: 10.1016/j.abb.2012.03.003

1. Thacher TD, Fischer PR, **Tebben PJ**, Singh RJ, Cha SS, Maxson JA, Yawn BP. Increasing incidence of nutritional rickets: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2013 Feb; 88

(2):176-83 PMID: 23374621 PMCID: 3612965 DOI: 10.1016/j.mayocp.2012.10.018

1. Berkseth KE, **Tebben PJ**, Drake MT, Hefferan TE, Jewison DE, Wermers RA. Clinical spectrum of hypophosphatasia diagnosed in adults. Bone. 2013 May; 54(1):21-7. Epub 2013 Jan 22. PMID: 23352924 DOI: 10.1016/j.bone.2013.01.024
2. Javed A, **Tebben PJ**, Fischer PR, Lteif AN. Female athlete triad and its components: toward improved screening and management. Mayo Clin Proc. 2013 Sep; 88(9):996-1009. PMID: 24001492 DOI: 10.1016/j.mayocp.2013.07.001
3. Gardner KH, Shon W, Folpe AL, Wieland CN, **Tebben PJ**, Baum CL. Tumor-induced osteomalacia resulting from primary cutaneous phosphaturic mesenchymal tumor: a case and review of the medical literature. J Cutan Pathol. 2013 Sep; 40(9):780-4; quiz 779. PMID: 23962115 DOI: 10.1111/cup.12209
4. Kundel A, Thompson GB, Richards ML, Qiu LX, Cai Y, Schwenk FW, Lteif AN, Pittock ST, Kumar S, **Tebben PJ**, Hay ID, Grant CS. Pediatric endocrine surgery: a 20-year experience at the Mayo Clinic. J Clin Endocrinol Metab. 2014 Feb; 99 (2):399-406 Epub 2013 Dec 11 PMID: 24423286 DOI: 10.1210/jc.2013-2617
5. \* James HA, Griebeler ML, **Tebben PJ**. 70-year-old woman with buttock pain and hypercalcemia. Mayo Clin Proc. 2014 Sep; 89(9):1313-7. PMID: 25192617 DOI: 10.1016/j.mayocp.2013.10.033
6. \* Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, **Tebben P**, Murad MH. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.

Osteoporos Int. 2015 Jul; 26(7):1875-91. Epub 2015 Jun 03. PMID: 26037791 DOI: 10.1007/s00198-015-3095-0

1. Uzodi AS, **Tebben PJ**, Boyce TG. Bone Pain in a 4-year-old Boy with Chronic Granulomatous Disease and History of Aspergillus pneumonia. Pediatr Infect Dis J. 2016 Apr; 35: (4)464-5, 469. PMID: 26967683 DOI: 10.1097/INF.0000000000001042
2. \* Trivedi S, Al-Nofal A, Kumar S, Tripathi S, Kahoud RJ, **Tebben PJ**. Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child. Osteoporos Int. 2016 Jul; 27 (7):2379-2382 Epub 2016 Feb 18 PMID: 26892041 DOI: 10.1007/s00198-016-3528-4
3. \* O'Keeffe DT, **Tebben PJ**, Kumar R, Singh RJ, Wu Y, Wermers RA. Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect. Osteoporos Int. 2016 Oct; 27 (10):3121-5 Epub 2016 Apr 29 PMID: 27129455 DOI: 10.1007/s00198-016-3615-6
4. **Tebben PJ**, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocr Rev. 2016 Oct; 37 (5):521-547 Epub 2016 Sept 02 PMID: 27588937 PMCID: 5045493 DOI: 10.1210/er.2016-1070
5. Gonzalez Ballesteros LF, Ma NS, Gordon RJ, Ward L, Backeljauw P, Wasserman H, Weber DR, DiMeglio LA, Gagne J, Stein R, Cody D, Simmons K, Zimakas P, Topor LS, Agrawal S, Calabria A, **Tebben P**, Faircloth R, Imel EA, Casey L, Carpenter TO. Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. Bone. 2017 Apr; 97:287-292 Epub 2017 Feb 04 PMID: 28167344 PMCID: 5884631 DOI: 10.1016/j.bone.2017.02.003
6. \* Kumar A, Wermers RA, **Tebben PJ**. Iron replacement as a therapeutic approach for renal phosphate wasting with associated iron deficiency AACE Clinical Case Reports.2017;3:(3)e260-e263. DOI: 10.4158/EP161330.CR
7. Sakka S, Gafni RI, Davies JH, Clarke B, **Tebben P**, Samuels M, Saraff V, Klaushofer K, Fratzl-Zelman N, Roschger P, Rauch F, Hogler W. Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome. J Clin Endocrinol Metab. 2017 Nov 1; 102 (11):4163- 4172 PMID: 28938420 PMCID: 5673271 DOI: 10.1210/jc.2017-01102
8. Creo AL, **Tebben PJ**, Fischer PR, Thacher TD, Pittock ST. Cardiac Arrest in a Vitamin D-Deficient Infant. Glob Pediatr Health. 2018; 5:2333794X18765064 Epub 2018 Mar 20 PMID: 29581997 PMCID: 5863858 DOI: 10.1177/2333794X18765064
9. \* Creo AL, Epp LM, Buchholtz JA, **Tebben PJ**. Prevalence of Metabolic Bone Disease in Tube-Fed Children Receiving Elemental Formula. Horm Res Paediatr. 2018; 90 (5):291-298 Epub 2018 Nov 29 PMID: 30497080 DOI: 10.1159/000494726
10. \* Hana Lo, Theresa Wampler Muskardin, **Peter J Tebben**. BLAU SYNDROME: AN UNUSUAL CAUSE OF HYPERCALCEMIA IN A CHILD AACE Clinical Case Reports. 2018; 4(4):e278-e281.
11. Dahl AR, Iqbal AM, Lteif AN, Pittock ST, **Tebben PJ**, Kumar S. Mild subclinical hypothyroidism is associated with paediatric dyslipidaemia. Clin Endocrinol (Oxf). 2018 Sep; 89 (3):330-335 Epub 2018 June 21 PMID:

29846957 DOI: 10.1111/cen.13752

1. Boland JM, **Tebben PJ**, Folpe AL. Phosphaturic mesenchymal tumors: what an endocrinologist should know. J Endocrinol Invest. 2018 Oct; 41 (10):1173-1184 Epub 2018 Feb 14 PMID: 29446010 DOI: 10.1007/s40618-018-0849-5
2. Gupta N, Lteif A, Creo A, Iqbal AM, Pittock S, **Tebben PJ**, Hansen J, Heyrman M, Spee R, Scanlan-Hanson L, Kumar S. Improved utilization of waist-to-height ratio in cardiometabolic risk counselling in children: Application of DMAIC strategy. J Eval Clin Pract. 2019 Apr; 25 (2):300-305 Epub 2018 Oct 31 PMID: 30378218 DOI: 10.1111/jep.13055
3. Thacher TD, Pettifor JM, **Tebben PJ**, Creo AL, Skrinar A, Mao M, Chen CY, Chang T, San Martin J, Carpenter TO. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. Bone. 2019 May; 122:76-81 Epub 2019 Feb 14 PMID: 30772600 DOI: 10.1016/j.bone.2019.02.010
4. Creo A, Anderson H, Cannon B, Lteif A, Kumar S, **Tebben P**, Iqbal AM, Ramakrishna A, Pittock S. Patterns of amiodarone-induced thyroid dysfunction in infants and children. Heart Rhythm. 2019 Sep; 16 (9):1436-1442 Epub 2019 Mar 21 PMID: 30904484 DOI: 10.1016/j.hrthm.2019.03.015
5. Weber DR, Boyce A, Gordon C, Hogler W, Kecskemethy HH, Misra M, Swolin-Eide D, **Tebben P**, Ward LM, Wasserman H, Shuhart C, Zemel BS. The Utility of DXA Assessment at the Forearm, Proximal Femur, and Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric Population: 2019 ISCD Official Position. J Clin Densitom. 2019 Oct - Dec; 22 (4):567-589 Epub 2019 July 10 PMID: 31421951 PMCID: 7010480 DOI: 10.1016/j.jocd.2019.07.002
6. \* Wadams HD, Gupta N, Novotny P, **Tebben PJ**. Onset of pituitary hormone deficiencies in optic nerve hypoplasia: a temporal trend analysis of 32 children at Mayo Clinic. J Pediatr Endocrinol Metab. 2020 Jan 28; 33 (1):139-145 PMID: 31811804 DOI: 10.1515/jpem-2019-0269
7. Muthusamy K, Macke E, Klee EW, **Tebben PJ**, Hand JL. Congenital Ichthyosis American Journal of Medical Genetics. 2020.
8. Muthusamy K, Macke EL, Klee EW, **Tebben PJ**, Hand JL, Hasadsri L, Marcou CA, Schimmenti LA. Congenital ichthyosis in Prader-Willi syndrome associated with maternal chromosome 15 uniparental disomy: Case report and review of autosomal recessive conditions unmasked by UPD. Am J Med Genet A. 2020 Oct; 182 (10):2442-2449 Epub 2020 Aug 20 PMID: 32815268 DOI: 10.1002/ajmg.a.61792
9. Eswarakumar AS, Ma NS, Ward LM, Backeljauw P, Wasserman H, Weber DR, DiMeglio LA, Imel EA, Gagne J, Cody D, Zimakas P, Topor LS, Agrawal S, Calabria A, **Tebben P**, Faircloth RS, Gordon R, Casey L, Carpenter TO. Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation. Clin Pediatr (Phila). 2020 Oct; 59 (12):1080-1085 Epub 2020 July 15 PMID: 32666808 DOI: 10.1177/0009922820941097
10. Muthusamy K, Hanna C, Johnson DR, Cramer CH, **Tebben PJ**, Libi SE, Poling GL, Lanpher BC, Morava E, Schimmenti LA. Growth hormone deficiency in a child with branchio-oto-renal spectrum disorder: Clinical evidence of EYA1 in pituitary development and a recommendation for pituitary function surveillance. Am J Med Genet A. 2021 Jan; 185 (1):261-266 Epub 2020 Oct 24 PMID: 33098377 DOI: 10.1002/ajmg.a.61942
11. Christensen S, **Tebben PJ**, Sas D, Creo AL. Variable Clinical Presentation of Children with Hereditary Hypophosphatemic Rickets with Hypercalciuria: A Case Series and Review of the Literature. Horm Res Paediatr 2021; 94 (9-10):374-389 Epub 2021 Oct 19 PMID: 34666334 DOI: 10.1159/000520299
12. Hawkes CP, Roy SM, Dekelbab B, Frazier B, Grover M, Haidet J, Listman J, Madsen S, Roan M, Rodd C, Sopher A, **Tebben P**, Levine MA. Hypercalcemia in Children Using the Ketogenic Diet: A Multicenter Study. J Clin Endocrinol Metab. 2021 Jan 23; 106 (2):e485-e495 PMID: 33124662 PMCID: 7823241 DOI: 10.1210/clinem/dgaa759
13. Qureshi MY, Patterson MC, Clark V, Johnson JN, Moutvic MA, Driscoll SW, Kemppainen JL, Huston J 3rd, Anderson JR, Badley AD, **Tebben PJ**, Wackel P, Oglesbee D, Glockner J, Schreiner G, Dugar S, Touchette JC, Gavrilova RH. Safety and efficacy of (+)-epicatechin in subjects with Friedreich's ataxia: A phase II, open- label, prospective study. J Inherit Metab Dis. 2021 Mar; 44 (2):502-514 Epub 2020 Aug 31 PMID: 32677106 DOI: 10.1002/jimd.12285
14. Gupta N, Gregory SW, Deyle DR, **Tebben PJ**. Three Patient Kindred with a Novel Phenotype of Osteogenesis Imperfecta due to a COL1A1 Variant J Clin Res Pediatr Endocrinol. 2021 Jun 2; 13 (2):218-224 Epub 2020 June 10 PMID: 32519829 PMCID: 8186326 DOI: 10.4274/jcrpe.galenos.2020.2020.0012
15. Zavatta G, **Tebben PJ**, McCollough CH, Yu L, Vrieze T, Clarke BL. Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2021 Jun 16; 106 (7):1900-1917 PMID: 33788935 DOI: 10.1210/clinem/dgab162
16. Hanna C, Potretzke TA, Cogal AG, Mkhaimer YG, **Tebben PJ**, Torres VE, Lieske JC, Harris PC, Sas DJ, Milliner DS, Chebib FT. High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency. Kidney Int Rep. 2021 Jul; 6 (7):1895-1903 Epub 2021 May 12 PMID: 34307984 PMCID: 8258502 DOI: 10.1016/j.ekir.2021.04.030
17. Azer SM, Vaughan LE, **Tebben PJ**, Sas DJ. 24-Hydroxylase Deficiency Due to CYP24A1 Sequence Variants: Comparison With Other Vitamin D-mediated Hypercalcemia Disorders. J Endocr Soc. 2021 Sep 1; 5 (9):bvab119 Epub 2021 July 02 PMID: 34337279 PMCID: 8317629 DOI: 10.1210/jendso/bvab119
18. Kiuchi Z, Reyes M, Hanna P, Sharma A, DeClue T, Olney RC, **Tebben P**, Juppner H. Progression of PTH Resistance in Autosomal Dominant Pseudohypoparathyroidism Type Ib Due to Maternal STX16 Deletions. J Clin Endocrinol Metab. 2022 Jan 18; 107 (2):e681-e687 PMID: 34477200 PMCID: 8899049 DOI: 10.1210/clinem/dgab660
19. Wang Z, Joshi A, Leopold K, Jackson S, Christensen S, Nayfeh T, Mohammed K, Creo A, **Tebben P**, Kumar

S. Association of vitamin D deficiency with COVID-19 infection severity: Systematic review and meta-analysis. Clin Endocrinol (Oxf). 2022 Mar; 96 (3):281-287 Epub 2021 July 12 PMID: 34160843 PMCID: 8444883 DOI: 10.1111/cen.14540

1. Hanna C, Potretzke TA, Chedid M, Rangel LJ, Arroyo J, Zubidat D, **Tebben PJ**, Cogal AG, Torres VE, Harris PC, Sas DJ, Lieske JC, Milliner DS, Chebib FT. Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series. Kidney Med. 2022 Mar; 4 (3):100419 Epub 2022 Jan 24 PMID: 35386604 PMCID:

8978140 DOI: 10.1016/j.xkme.2022.100419

1. Milioto A, Reyes M, Hanna P, Kiuchi Z, Turan S, Zeve D, Agarwal C, Grigelioniene G, Chen A, Mericq V, Frangos M, Ten S, Mantovani G, Salusky IB, **Tebben P**, Juppner H. Lack of GNAS Remethylation During Oogenesis May Be a Cause of Sporadic Pseudohypoparathyroidism Type Ib. J Clin Endocrinol Metab. 2022 Mar 24; 107 (4):e1610-e1619 PMID: 34791361 PMCID: 8947795 DOI: 10.1210/clinem/dgab830
2. Dahl AR, Armellino AL, Tran CL, **Tebben PJ**. Skimmed breast milk for treatment of hypertriglyceridemia in an infant with congenital nephrotic syndrome. Nutr Clin Pract. 2022 Apr; 37 (2):383-387 Epub 2021 Sept 06 PMID: 34486165 DOI: 10.1002/ncp.10759
3. **Tebben PJ**. Hypophosphatemia: A Practical Guide to Evaluation and Management. Endocr Pract. 2022 Oct; 28 (10):1091-1099 Epub 2022 Aug 06 PMID: 35940468 DOI: 10.1016/j.eprac.2022.07.005
4. Szabo Yamashita T, Gudmundsdottir H, Foster TR, Lyden ML, Dy BM, **Tebben PJ**, McKenzie T. Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases. Am J Surg. 2022 Oct 17. [Epub ahead of print] PMID: 36270819 DOI: 10.1016/j.amjsurg.2022.10.018
5. Szabo Yamashita T, Gudmundsdottir H, Foster TR, Lyden ML, Dy BM, **Tebben PJ**, McKenzie T. Pediatric primary hyperparathyroidism: Surgical pathology and long-term outcomes in sporadic and familial cases. Am J Surg. 2023 Apr;225(4):699-702. doi: 10.1016/j.amjsurg.2022.10.018. Epub 2022 Oct 17. PMID: 36270819.
6. Pinto E Vairo F, Kemppainen JL, Vitek CRR, Whalen DA, Kolbert KJ, Sikkink KJ, Kroc SA, Kruisselbrink T, Shupe GF, Knudson AK, Burke EM, Loftus EC, Bandel LA, Prochnow CA, Mulvihill LA, Thomas B, Gable DM, Graddy CB, Garzon GGM, Ekpoh IU, Porquera EMC, Fervenza FC, Hogan MC, El Ters M, Warrington KJ, Davis JM 3rd, Koster MJ, Orandi AB, Basiaga ML, Vella A, Kumar S, Creo AL, Lteif AN, Pittock ST, **Tebben PJ**, Abate EG, Joshi AY, Ristagno EH, Patnaik MS, Schimmenti LA, Dhamija R, Sabrowsky SM, Wierenga KJ, Keddis MT, Samadder NJJ, Presutti RJ, Robinson SI, Stephens MC, Roberts LR, Faubion WA Jr, Driscoll SW, Wong-Kisiel LC, Selcen D, Flanagan EP, Ramanan VK, Jackson LM, Mauermann ML, Ortega VE, Anderson SA, Aoudia SL, Klee EW, McAllister TM, Lazaridis KN. Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD). J Transl Med. 2023 Jun 23;21(1):410. doi: 10.1186/s12967-023-04183-7. Erratum in: J Transl Med. 2024 Apr 30;22(1):400. doi: 10.1186/s12967-024-05185-9. PMID: 37353797.
7. Shariq OA, Abrantes VB, Lu LY, **Tebben PJ**, Foster TM, Dy BM, Lyden ML, Young WF, McKenzie TJ. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: Impact of genotype and surgical approach on long-term postoperative outcomes. Surgery. 2024 Jan;175(1):8-16. doi: 10.1016/j.surg.2023.05.044. Epub 2023 Oct 25. PMID: 37891063.
8. Salama M, **Tebben PJ**, Al Nofal A. An infant developing hypercalcemia and hypophosphatemia due to the use of exclusively almond milk. J Pediatr Endocrinol Metab. 2024 Feb 29;37(4):375-379. doi: 10.1515/jpem-2023-0494. PMID: 38414167.
9. Mohan S, Sheehan M, **Tebben P**, Wermers R. Efficacy of Oral Cinacalcet in Non-PTH Nonmalignant Hypercalcemia from Excess 1,25-Dihydroxyvitamin D. JCEM Case Rep. 2024 Mar 12;2(3):luae022. doi: 10.1210/jcemcr/luae022. PMID: 38476635; PMCID: PMC10928506.
10. Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter TO, Lazaretti-Castro M, Colazo JM, McCrystal Dahir K, Geßner M, Gurevich E, Heier CA, Simmons JH, Hunley TE, Hoppe B, Jacobsen C, Kouri A, Ma N, Majumdar S, Molin A, Nokoff N, Ott SM, Peña HG, Santos F, **Tebben P**, Topor LS, Deng Y, Bergwitz C. An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Kidney Int. 2024 May;105(5):1058-1076. doi: 10.1016/j.kint.2024.01.031. Epub 2024 Feb 15. Erratum in: Kidney Int. 2024 Jul;106(1):159. doi: 10.1016/j.kint.2024.05.005. PMID: 38364990; PMCID: PMC11106756.

**Non-Peer-reviewed Articles**

1.

1. Lteif A, **Tebben P**, Thompson G. Graves' Disease in Children Endocrinology Update. 2007 December; 2(4).
2. **Tebben P**, McIntosh A. Childhood Fractures, When to Worry Endocrinology Update. 2009 December; 4(4).

**Book Chapters**

1. **Tebben PJ**, Kumar R. Fanconi syndrome and renal tubular acidosis. In: Favus MJ. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington, DC: American Society for Bone and Mineral Research; 2003. p. 426-30.
2. **Tebben PJ**, Kumar R. Vitamin D and the kidney. In: Feldman D. Vitamin D. 2nd ed. Burlington, MA: Elsevier Academic Press; 2004. p. 515-36.
3. **Tebben PJ**, Kumar R. The hormonal regulation of calcium metabolism. In: Editors: Alpern RJ and Hebert SC. The Kidney: Physiology and Pathophysiology: Clinical and Physiologic Phosphate Disturbances 4th Edition ed. Elsevier Academic Press; 2005. p. 1891-1910.
4. **Tebben PJ**, Thomas LF, Kumar R. Fanconi syndrome and renal tubular acidosis. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: 2006. p. 354-8.
5. Kudva YC, Khoo TK, **Tebben PJ**. The patient with type 1 diabetes and hypoglycemia. In: Montori VM, editor. Evidence-based endocrinology. Totowa: Humana Press; 2006. (Contemporary Endocrinology.). p. 259-73.
6. **Tebben PJ**, Schwenk WF. Diabetes mellitus. In: McInerny TK, Adam HM, Campbell D, Kamat DK, Keller KJ. Pediatric primary care. 5th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2008.
7. **Tebben PJ**, Schwenk WF. Diabetic Ketoacidosis. In: McInerny TK, Adam HM, Campbell D, Kamat DK, Keller KJ. Pediatric Primary Care 5th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2008.
8. **Tebben PJ**, Berndt TJ, Kumar R. Phosphatonins. In: Marcus R, et al, editors. Osteoporosis. 3rd Edition. Volume 1. Amsterdam; Boston: Elsevier Academic Press; 2008. p. 451-66.
9. **Tebben PJ**, Kumar R. The hormonal regulation of calcium metabolism. In: Seldin and Giebisch's the kidney. 2008. p. 1891-909.
10. McIver B, **Tebben PJ**, Shah P. Endocrinology. In: Ghosh AK; et al, editor. Mayo Clinic internal medicine board review. 9th Edition. Rochester: Mayo Clinic Scientific Press; 2010. p. 185-231.
11. **Tebben PJ**, Berndt TJ, Kumar R. Phosphatonins. In: Marcus R; et al, editor. Fundamentals of osteoporosis. Burlington; London: Academic Press; 2010. p. 413-28.
12. **Tebben PJ**, Kumar R. Hormonal Regulation of Calcium Metabolism. In: Alpern RJ and Hebert SC. The Kidney: Physiology and Pathophysiology: Clinical and Physiologic Phosphate Disturbances 5th Edition ed. Elsevier Academic Press; 2011 (In Press).
13. **Tebben P**, Kumar R. Vitamin D and the kidney. In: Feldman D; Pike JW; Adams JS editor. Vitamin D. 3rd Edition. London; Waltham: Academic Press; 2011. p. 471-91.
14. **Tebben P**. Hypocalcemia. In: Endocrine Self-Assessment Program 2013 - In press.
15. **Tebben PJ**, Berndt TJ, Kumar R. Phosphatonins. In: Osteoporosis. Fourth ed. 2013. p. 373-90.
16. **Tebben PJ**, Kumar R. The hormonal regulation of calcium metabolism. In: Seldin and Geibisch's the kidney. Volume 2. 2013. p. 2249-72.
17. Lo HB, **Tebben PJ**. Primary hyperparathyroidism in children and adolescents. In: Kearns AE; Wermers RA, Hyperparathyroidism: a clinical casebook. 2016. p. 117-28.
18. Javed A, Schwenk WF, **Tebben P**. Diabetes mellitus. In: McInerny TK; et al editors., American Academy of Pediatrics textbook of pediatric care. 2nd Edition. Elk Grove Village: American Academy Of Pediatrics; 2017.

p. 1952-62.

1. Al Nofal A, Schwenk WF, **Tebben P**. Diabetic ketoacidosis. In: McInerny TK; et al editors., American Academy of Pediatrics textbook of pediatric care. 2nd Edition. Elk Grove Village: American Academy Of Pediatrics; 2017. p. 2813-9.
2. **Tebben PJ**, Kumar R. Vitamin d and the kidney. In: Feldman D; Et al editors., Vitamin D. Volume 1, Biochemistry, physiology and diagnostics. Fourth Edition. Volume 1. London; San Diego: Elsevier/Academic Press; 2017. vol. 1. p. 437-59.
3. Kritmetapak K, Tebben PJ, Kumar R. Vitamin d and the kidney. In: Hewison M; Et al editors., Feldman and Pike's vitamin d: biochemistry, physiology and diagnostics. Fifth Edition. London: Academic Press/Elsevier; 2024. vol. One. p. 301-30.

**Abstracts**

1. **Tebben PJ**, Fatourechi V. Development of Graves’ disease under adequate immunosuppression in a cardiac transplant patient. American Thyroid Association Conference. 2003.
2. **Tebben PJ**, Hurley DL, Kennel KA, Collazo-Clavell ML. Elevation of alkaline phosphatase levels after roux-en- y gastric bypass: a retrospective review. North American Association for the Study of Obesity Conference.

2003.

1. **Tebben PJ**, Erickson D. Granulomatous hypophysitis after interferon alfa and ribavirin therapy. The Endocrine Society Conference. 2003.
2. **Tebben PJ**, Singh RJ, Bungum AO, Kumar R. Elevated serum fibroblast growth factor 23 in patients with small cell and squamous cell lung cancer with normal serum phosphorus. American Society for Bone and Mineral Research. 2004.
3. **Tebben PJ**, Kalli KR, Cliby WA, Hartmann LC, Singh RJ, Kumar R. Elevated serum fibroblast growth factor 23 without changes in phosphorus in women with advanced stage malignant ovarian tumors. American Society for Bone and Mineral Research. 2004.
4. **Tebben PJ**, Clarke, BL, Singh RJ, Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1 alpha, 25 dihydroxyvitamin D in surgically treated primary hyperparathyroidism. American Society for Bone and Mineral Research. 2004.
5. **Tebben PJ**, Leffert JD, Clarke BL, Thompson GB, Lloyd RV. A difficult case of parathyroid carcinoma. American Society for Bone and Mineral Research (Adult Bone and Mineral Working Group). 2005;
6. **Tebben PJ**, Hodgson SF, Clarke BL, Mullan BP, Cooney WP, Shives TJ. Whole body 99m-Tc sestamibi scintigraphy to localize tumors causing oncogenic osteomalacia. American Association of Clinical Endocrinology. 2005.
7. Berndt T, Craig T, Bielesz B, **Tebben P**, Bacic D, Wagner C, O'Brien S, Schiavi S, Biber J, Murer H, Kumar

R. Secreted frizzled related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells (Abstract SA455). J Bone Miner Res. 2005 Sep; 20(Suppl 1):S177.

1. **Tebben PJ**, Lteif, A. Hypophosphatasia in a Child with Overgrowth Syndrome. Endocrine Society –. 2006;
2. Kumar S, **Tebben P**, Reed A, Kuntz N. Hypopituitarism and Hypothalamic Dysfunction Associated with Autoimmune Encephalopathy. Lawson Wilkins Pediatric Endocrine Society –. 2006;
3. **Tebben P**, Wenkert D, Novack DV, DiMeglio LA, Sedighi H, McAlister W, Mumm S, Whyte MP. A new pediatric sclerosing bone disorder featuring fragility fractures. J Bone Miner Res. 2006 Sep; 21(Suppl 1):S432.
4. **Tebben PJ**, Tiegs RD, Clarke BL. Use of teriparatide in Hajdu-Cheney syndrome. J Bone Miner Res. 2007 Sep; 22(Suppl 1):S502.
5. Paulo RC, **Tebben PJ**. Renal Fanconi Syndrome and Hypoparathyroidism Associated with a Mitochondrial DNA Deletion Syndrome. AACE. 2008.
6. Whyte M, Wenkert D, Zhang F, McAlister WH, **Tebben P**, Bowcock AM, Mumm S. Chromosomal Localization of Four Autosomal Dominant Skeletal Diseases, Including Osteogenesis Imperfecta Type V and Meta chondromatosis. American Society for Bone and Mineral Research Annual Meeting Denver, CO. 2009.
7. Hay ID, Gonzalez-Losada T, Hutchinson M, Reinalda M, Honetschlager J, **Tebben PJ**, Richards M, Thompson

G. Long-term outcome in 215 children and adolescents with papillary thyroid cancer (PTC) treated during 1940 through 2008. International Surgical Week. 2009.

1. Wermers R, Hefferan T, Berkseth K, Jewison D, Drake M, Yaszemski M, **Tebben P**. Bone Histomorphometry in Hypophosphatasia Diagnosed in Adults. ASBMR Annual Meeting. 2010; MO0443:263.
2. Berkseth KE, **Tebben PJ**, Wermers RA. Clinical spectrum of hypophosphatasia diagnosed in adults. Endocr Rev. 2010 Jun; 31(Suppl 1).
3. Sinaki M, Hurley D, Wermers R, **Tebben P**, Kennel K, Drake M. Vertebral Compression Fractures Resulting from Strenuous Recreational Exercise: When Good Intentions Crumble. J Bone Miner Res. 2010 Oct; 25(Suppl 1):S467.
4. Nannenga MR, **Tebben PJ**, Nippoldt T. Dopamine Agonists and Compulsive Disorders. Endocrine Society Annual Meeting Boston MA. 2011.
5. Thacker TD, Fischer PR, **Tebben PJ**, Singh RJ, Cha S, Yawn BP. Incidence of Nutritional Rickets in Olmsted County Minnesota. American Society of Bone and Mineral Research Annual Meeting San Diego CA. 2011.
6. Kumar RJ, **Tebben P**, Milliner DS, Harris PC, Horst R, Foreman JW, Chelminski P. Successful treatment with ketoconazole of a syndrome with hypercalcemia, hypercalciuria, nephrolithiasis, nephrocalcinosis, elevated serum calcitriol and mutations in the 24-hydroxylase (CYP24A1) gene. Journal of the American Society of Nephrology. 2011; 22:85A.
7. **Tebben PJ**, Milliner DS, Horst R, Kumar R. A novel syndrome characterized by intermittent hypercalcemia, hypercalciuria, elevated serum calcitriol and undetectable 24, 25-dihydroxyvitamin D concentrations, nephrolithisis, osteoporosis, and mutations in the *CYP24A1*(25-hydroxyvtamin D/1, 24-Di). American Society for Bone and Mineral Research Annual Meeting, San Diego, CA. September 16-20, 2011.
8. Berkseth K, **Tebben P**, Drake M, Wermers R. Hypophosphatasia Diagnosed in Adults: Differential Features Based on Sex, Presence of Fractures, and Symptoms at Presentation. J Bone Miner Res. 2012; 27 (Supp 1):SA0354.
9. Gardner K, Shon W, Folpe A, Weiland C, **Tebben P**, Baum C. Tumor-Induced Osteomalacia Resulting from Primary Cutaneous Phosphaturic Mesenchymal Tumor: A Case and Review of the Medical Literature. Summer Academy of Dermatology. 2013.
10. Luisa F Gonz&#225;lez Ballesteros, Nina Ma, Leanne Ward, Philippe Backeljauw, Halley Wasserman, David Weber, Linda DiMeglio, Julie Gagne, Robert Stein, Declan Cody, Kimber Simmons, Paul Zimakas, Lisa Swartz Topor, Sungeeta Agrawal, Rebecca Gordon, **Peter Tebben**, Ruth Faircloth, Linda Casey, Erik Imel, Thomas O Carpenter. Hypophosphatemia Associated with Elemental Formula Use in Children with Feeding Problems. ASBMR. 2015. Epub 2015
11. Sangita Trivedi MBBS, Alaa Al-Nofal MD, Seema Kumar MD, Sandeep Tripathi MD, Robert J, Kahoud MD, **Peter J Tebben MD**. Severe, Non-infective SIRS, Shock, and End Organ Dysfunction after Zoledronic Acid. ASBMR. 2015. Epub 2015
12. Keeffe BM, BCh, BAO, Ph.D, **Peter J Tebben MD**, Rajiv Kumar MD, Ravinder J Singh Ph.D, Yanhong Wu Ph.D, Robert A, Wermers MD. The Spectrum of Clinical and Biochemical Phenotypes in Adults with Familial CYP24A1 Mutations. ASBMR. 2015. Epub 2015
13. **Tebben PJ**, Trivedi S, Al Nofal A, Kumar S, Tripathi S, Kahoud R. Severe, Non-Infective Systemic Inflammatory Response Syndrome, Shock, and End Organ Dysfunction after Zoledronic Acid Administration in a Child Critical Care Med.2015;43:(12) Abstract no.1281.
14. \* Hana Lo, Wampler-Muskardin Theresa, **Tebben Peter**. Blau Syndrome: An Unusual Cause Of Hypercalcemia In A Child Endocrine Reviews. 2016; 37(2 Supplement).
15. Gupta N, Lteif A, Creo A, Iqbal AM, Schwenk F, Pittock S, **Tebben PJ**, Hansen J, Heyrman M, Spee R, Scanlan-Hanson L, Kumar S. Improved frequency of waist circumference measurement and utilization of waist-to-height ratio in cardiometabolic risk counselling among children: A quality improvement initiative Hormone Research In Paediatrics. 2017; 88 (Suppl 1):189
16. Gupta N, **Tebben PJ**. Short stature without hypertrichosis cubiti: Atypical phenotype of Wiedemann-Steiner syndrome with a novel nonsense kmt2a (mll) mutation Hormone Research In Paediatrics. 2017; 88 (Suppl 1):307-8
17. \* Ana Creo, Lisa Epp, Julie Buchholtz, **Peter Tebben**. Metabolic Bone Disease in Children Receiving Elemental Formula ASBMR Annual Meeting. 2017.
18. \* Heather D Wadams, Nidhi Gupta, **Peter J. Tebben**. Onset of Pituitary Hormone Deficiencies in Optic Nerve Hypoplasia: A Temporal Trend Analysis Endocrine Reviews. 2018; 39(2).
19. Thacher TD, Pettifor JM, **Tebben PJ**, Creo AL, Skrinar A, Mao M, Chen CY, Chang T, San J, Carpenter TO. The relationship of radiographic rickets severity score with clinical outcomes in children with x-linked hypophosphatemia European Calcified Tissue Society Meeting 2019. 2019.
20. \* Christensen SL, **Tebben PJ**, Sas D, Creo AL. Variable Clinical Presentation of Children With Hereditary Hypophosphatemic Rickets With Hypercalciuria: A Case Series Endocrine Society. 2021
21. Salama M, Pinto e Vairo F, Hentz R, Al Nofal A, Hassan S, Ibrahim S, Lteif A, Pittock ST, **Tebben PJ**, Creo A, Kumar S. Anthropometric and laboratory features in children with obesity with and without variants in monogenic obesity-related genes. Hormone Research in Paediatrics. 2023 Jul 26; 96(Suppl 3):263-4

**Ask Mayo Expert Model**

1. **Tebben P**, Larson AN. Recurrent Fractures (Pediatric) In: Ask Mayo Expert Care Process Model. 2013. Available from: <http://javaprod.mayo.edu/ame/openTopic?collection=1&topicID=4423>
2. Lteif A, **Tebben PJ**, Erickson D, Castro MR, Kennel KA. Diabetes insipidus and polyuria (child) AskMayoExpert.2018
3. Kennel KA, **Tebben PJ**. Prevention of recurrent fractures (adult) In: AskMayoExpert. 03-29-2019. Available from: [http://askmayoexpert.mayoclinic.org](http://askmayoexpert.mayoclinic.org/)

\* Indicates the primary author was a mentee of Dr. Tebben.

# Indicates the authors contributed equally.